GPT and fatty liver disease: Previous studies from our laboratory have demonstrated that Sch B treatment increased serum and hepatic TG levels, serum alanine aminotransferase (ALT) activity and hepatic mass in mice, suggestive of a mouse model of hypertriglyceridemia combined with hepatic steatosis and injury [19–21].